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Identification of a Mycobacterium tuberculosis gene cluster 
encoding the biosynthetic enzymes for assembly of the 
virulence-conferring siderophore mycobactin 
Luis EN Quadri, Jason Sello, Thomas A Keating, Paul H Weinreb 
and Christopher T Walsh 
Background: Many pathogenic bacteria secrete iron-chelating siderophores as 
virulence factors in the iron-limiting environments of their vertebrate hosts to 
compete for ferric iron. Mycobacterium tuberculosis mycobactins are mixed 
polyketide/nonribosomal peptides that contain a hydroxyaryloxazoline cap and 
two N-hydroxyamides that together create a high-affinity site for ferric ion. The 
mycobactin structure is analogous to that of the yersiniabactin and vibriobactin 
siderophores from the bacteria that cause plague and cholera, respectively. 
Results: A ten-gene cluster spanning 24 kilobases of the M. tuberculosis 
genome, designated mbfA-J, contains the core components necessary for 
mycobactin biogenesis. The gene products Mb@, MbtE and MbtF are proposed 
to be peptide synthetases, MbtC and MbtD polyketide synthases, Mbtl an 
isochorismate synthase that provides a salicylate activated by MbtA, and MbtG a 
required hydroxylase. An aryl carrier protein (ArCP) domain is encoded in mbtB, 
and is probably the site of siderophore chain initiation. Overproduction and 
purification of the mbtB ArCP domain and MbtA in Escherichia coliallowed 
validation of the mycobactin initiation hypothesis, as sequential action of PptT (a 
phosphopantetheinyl transferase) and MbtA (a salicyl-AMP ligase) resulted in the 
mbtB ArCP domain being activated as salicyl-S-ArCP. 
Conclusions: Mycobactins are produced in M. tuberculosis using a polyketide 
synthase/nonribosomal peptide synthetase strategy. The mycobactin gene 
cluster has organizational homologies to the yersiniabactin and enterobactin 
synthetase genes. Enzymatic targets for inhibitor design and therapeutic 
intervention are suggested by the similar ferric-ion ligation strategies used in the 
siderophores from Mycobacteria, Yersinia and E. coli pathogens. 
Introduction 
The ability of the pathogenic Mycobactetium tuberculosis to 
grow in its animal and human hosts, especially in iron- 
limited extracellular spaces such as respiratory cavities, is 
dependent on its ability to scavenge iron. Like many other 
bacterial pathogens, M. t~derculosis [l] and M. avium [2,3], 
the latter an important opportunistic pathogen in immuno- 
compromised patients, synthesize and secrete specialized 
iron chelators known as siderophores (which confer viru- 
lence on the pathogen), and then specifically take up 
those complexed with ferric iron. 
Fast growing, nonpathogenic mycobacteria such as 
M. smegmatis make and secrete water-soluble, peptide- 
based hydroxamate-containing siderophores (exoche- 
lin MS [4]) and membrane-associated siderophores 
(mycobactin S [5]). Slow growing pathogens such as 
M. tz&erczllosis and M. avium produce the membrane-asso- 
ciated mycobactin T and water-soluble siderophores 
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called, generically, exochelins [6] or carboxymycobactins 
[7], which differ structurally from the exochelin MS pro- 
duced by M. smegmatis [4]. Recent structural analysis of 
mycobactins and carboxymycobactins (exochelins) indi- 
cates these peptides are highly related in their core struc- 
tures and vary mainly in their fatty acid substituents 
(Figure 1) [1,3,7]. The lipid-soluble mycobactins have 
long chain (ClS-21) saturated or monounsaturated acyl 
chains on the first lysine residue, whereas the water 
soluble carboxymycobactins have a shorter ((Z-9) side- 
chain that terminates with a carboxylic acid or methyl 
ester. It has been suggested that the carboxymycobactins 
pass ferric ions to the membrane-associated mycobactins 
on their way into the mycobacterial cell [S]. Most notably, 
the tubercular carboxymycobactins and mycobactins both 
contain, as a modified N-acylated amino terminus, a 
hydroxyphenyloxazoline moiety linked by an amide to 
a lysine residue both hydroxylated and acylated on 
its E-amino group. A polyketide fragment and second 
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Figure 1 
Yersiniabactin Anguibactin 
Pyochelin Mycobactins: R = CH3, x = O-17, y = 0, 1,14-17 
Carboxymycobactins: R = COOH, COOMe, 
x=1-9,y=o,1 
Methyl 2-(2’-hydroxyphenyl)- 
2-oxazoline-4-carboxylate 
Formobactin: RI = H, Rp= Me H Vibriobactin 
Nocobactin NA: R, = Me, R2 = H 
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Aryl N-capped oxazoline- or thiazoline- 
containing siderophores. Mycobactins 
(membrane-associated) [38] and exochelins/ 
carboxymycobactins (water-soluble) [7] have 
been isolated from Mycobacterium sp., and 
differ mainly in the length and hydrophobicity of 
the N-acyl group. Variable moieties are shown 
in red. The structurally related formobactin and 
nocobactin NA from Nocardia sp. are shown in 
the lower left [14], again with the variable 
regions in red. Also depicted are yersiniabactin 
[l 11 from Yersinia pesfis, acinetobactin [9] 
from Acinefobacfer baumani, anguibactin [12] 
from vibrio anguillarum, pyochelin [13] from 
Pseudomonas aeruginosa, vibriobactin [lo] 
from vibrio cholerae and methyl-2- 
(2’-hydroxyphenyl)-2-oxazoline-4carboxylate 
[39] from Actinomadura sp. 
&-N-hydroxy-lysine (cyclized to the seven-membered ring 
hydroxamate) follow. In M. tuberculosis, mycobactins with 
and without a methyl group on the S-position of the oxazo- 
line ring have .been isolated, indicating incorporation of 
both serine and threonine residues. In contrast, in 
M. av&n only the methyloxazoline ring is detected, indi- 
cating a biosynthetic preference for threonine [7]. In this 
work, for purposes of clarity, the term mycobactin refers to 
the skeleton characteristic of the M. tzlderczclosis carboxy- 
mycobactins and mycobactin T. 
These mycobactins are members of a substantial bacterial 
class of siderophore natural products; synthesis of all 
siderophores is initiated using hydroxyaryl groups with 
amide linkages to serine, threonine or cysteine residues, 
which then undergo cyclodehydration to oxazoline (acine- 
tobactin [9], vibriobactin [lo] and mycobactins), thiazoline 
(yersiniabactin [l 11, anguibactin [ 121 and pyochelin [ 131) 
or oxazole (formobactin [14]) moieties (Figure 1, Zc,d). 
The mycobactins bear a striking resemblance to the viru- 
lence-conferring siderophore yersiniabactin [ 11,151 
(Figure 1) of the plague bacterium Yersinia pestis. This 
resemblance is notable not only in chain initiation, by 
which a comparable hydroxyphenylthiazoline is assem- 
bled in yersiniabactin, but also in the polyketide fragment 
inserted between the second and third amino acids (serine 
or threonine and lysine in mycobactin, and cysteine and 
cysteine in yersiniabactin). We recently demonstrated [ 161 
that the hydroxyphenylthiazoline moiety structure arises 
during yersiniabactin synthesis through the cyclization of a 
salicyl (Sal)-Cys-S-enzyme intermediate, in turn formed 
from distinct Sal-S-enzyme and Cys-S-enzyme covalent 
intermediates (Figure 2%~). Both sulfur atoms in the aryl-S- 
enzyme and Cys-S-enzyme forms are provided by the 
terminal thiol of a post-translationally introduced 4’-phos- 
phopantetheinyl (P-pant) group [17] at the aryl carrier 
protein (ArCP) and peptidyl carrier protein (PCP) domains, 
respectively, on the HMWP’2 component of yersiniabactin 
synthetase. The first 100 residues of yersiniabactin syn- 
thetase comprise the ArCP domain, thus aryl-S-ArCP for- 
mation is the initiation event in natural-product chain 
growth. Analogous aryl-N-capping initiates biosynthesis of 
enterobactin [18], the Eschendia colz siderophore, as well as 
the ,antibiotic actinomycin [ 191, reflecting a common strat- 
egy for a group of nonribosomally synthesized peptides. 
Reasoning that the molecular logic for mycobactin biogene- 
sis might also involve an aryl-N-capping of a Ser-S-enzyme 
or Thr-S-enzyme intermediate to form the first amide 
bond, presumably prior to heterocyclization (Figure Zd), we 
searched the sequenced M. tzcberczl~ososis genome from the 
strains CSU93 (being sequenced by The Institute for 
Genomic Research, TIGR, ftp://ftp.tigr.org/pub/data/ 
m-tuberculosis/) and H37Rv (sequenced by The Sanger 
Centre, http://www.sanger.ac.uk/Projects/M-tuberculosis) 
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Figure 2 
Priming and loading of carrier protein 
domains and chain initiation of various 
siderophore biosyntheses. Both the (a) aryl 
carrier protein (ArCP) and (b) peptidyl 
carrier proteins are comprised of 
approximately 100 amino-acid residues. A 
conserved serine residue in the apo carrier 
protein is first post-translationally modified by 
attachment of a phosphopantetheinyl 
prosthetic group derived from coenzyme A, 
catalyzed by a phosphopantetheinyl 
transferase (PPTase). The resulting holo 
enzyme is then loaded with the appropriate 
substrate via the AMP ester. 
(c) Yersiniabactin chain initiation begins with 
condensation of salicylate (from an ArCP 
thioester donor) with a peptidyl carrier 
protein (PCP)-bound cysteine residue. 
Cyclization to form the thiazoline ring follows. 
(d) Proposed mycobactin chain initiation is 
similar, except that salicylate is first 
transferred to a serine or threonine acceptor 
before the resulting intermediate is cyclized 
to an oxazoline ring. 
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for a gene cluster that contains the appropriate functional 
domains. We describe the organization of a ten-gene cluster 
that we term m&A-J (Figure 3), in concordance with the 
recent publication of the complete M. tubercdosis genome 
[ZO], along with a separate eleventh gene, pptT, that has 
homology to apo-PCP-recognizing phosphopantetheinyl 
transferases [17]. Expression and purification of the ArCP 
domain of MbtB (P-pant acceptor), of PptT (PPTase) and 
of MbtA (Sal-AMP ligase) allowed demonstration of the for- 
mation of the Sal-S-ArCP as the starter unit for mycobactin 
chain assembly (Figure Za). 
Results 
Identification of the mycobactin synthetase gene cluster 
and analysis of domain boundaries 
A search of the genomes of M. t&ercuLososis strains CSU93 
and H37Rv focused on proteins with homology to the 
yersiniabactin synthetase subunit HMWPZ [16] and to a 
fragment from bacitracin synthetase subunit Al [Zl], the 
latter including, the heterocyclization moiety of bacitracin. 
Open reading frames (ORFs) with appropriate homology 
were analyzed further for the presence of the following 
functional domains: three peptide synthetase adenylation 
domains, one for activation of serine or threonine, and two 
for lysine; polyketide synthase domains for the 3-hydroxy- 
butyrate fragment; a Sal-AMP ligase for the activation and 
transfer of a salicyl group; and, most particularly, an ArCP 
domain at the amino terminus of one of the peptide syn- 
thetases, which would contain a heterocyclization domain 
as the initiation site for mycobactin chain assembly. The 
search eventually led to the 24 kilobase region shown 
schematically in Figure 3a. There are ten ORFs in this 
region listed in Table 1 (characteristic signature motifs are 
listed in Figure 4). The proposed multidomain organization 
of the Mbt proteins is outlined in Figure 3b. At the conclu- 
sion of this work, the complete genome of M. &berculosis 
strain H37Rv was published by Cole et al. [ZO], and they 
have suggested, from homology alone, that these genes 
could encode the mycobactin biosynthetic proteins. We 
have adopted here the same letter designation proposed by 
Cole et al. [ZO] for the V.&Z genes. 
MbtB, MbtE and MbtF contain signature motifs for amino- 
acid adenylation domains and condensation domains, char- 
acteristic of nonribosomal peptide synthetases [ZZ]. Of 
particular interest is the MbtA gene product, which has 
extensive homology to both E. coli EntE (2,3-dihydroxy- 
benzoyl-AMP ligase) [23] and YbtE (salicyl-AMP ligase) 
[16], making it the prime candidate for the arylating 
enzyme involved in the initiation of mycobactin chain 
growth (Figure 5a). MbtB, MbtD, MbtE and MbtF collec- 
tively contain seven consensus sequences that are potential 
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Figure 3 
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(a) Organization of mbf genes in the mycobactin gene cluster (in base 
pairs), (b) domain arrangement of the peptide synthetase and 
polyketide synthase subunits and (c) structure of mycobactin T from 
M. tuberculosis, with alternating colors for the separately derived 
subunits. (The complete stereochemistry for mycobactin T is unknown, 
including the amino-acid configuration, and therefore none is 
depicted.) The following domains have been indicated: adenylation 
domain (A, dark green except for MbtA in light green), condensation 
(C, light yellow), thioesterase (TE, orange), epimerase (E, red), 
ketoacyl-ACP-synthase (KS, gray), acyltransferase (AT, gray), 
ketoreductase (KR, gray), cyclization domain (Cy, dark yellow), and 
carrier proteins (ArCP, PCPs and ACPs, blue tones). The P-pant 
groups attached to the carrier protein domains and the predicted 
precursor moieties for the mycobactin structure are indicated in (c). It 
is not clear what precursor moiety should be assigned to PCP3; this is 
indicated with a question mark. 
sites for post-translational phosphopantetheinylation domains (one for each amino acid in mycobactin), a fourth 
(Figure 4g). Although only three PCP domains would be PCP domain has been identified at the carboxyl terminus of 
expected, based on the presence of three adenylation MbtE, the function of which is as yet unclear. We have 
Table 1 
Characteristics and designation of proteins proposed for mycobactin biosynthesis in M. tuberculosis. 
Protein name Proposed function Amino acids Molecular weight (Da)* Gene name PID’ 
Mbtl (TrpE2)* 
MbtJ (LipK)* 
MbtA 
MbtB 
MbtC 
MbtD 
MbtE 
MbtF 
MbtG 
MbtH 
PptT 
AcpS 
lsochorismate synthase 431 46976.5 
Acetyl hydrolase 306 32875.9 
Salicylate-AMP ligase 565 59279.7 
Peptide synthetase 1413 151502.3 
Polyketide synthase 444 46623.4 
Polyketide synthase 1004 105591.5 
Peptide synthetase 1682 183282.0 
Peptide synthetase 1461 156747.7 
Lysine-/I-oxygenase 131 46943.0 
Unknown 57 6521.3 
PPTase 227 24707.5 
PPTase 130 14001.8 
mbfl (trpE2) 
mbtJ (/ipK) 
mbtA 
mbtB 
mbtC 
mbtD 
mbtE 
mbtF 
mbtG 
mbtH 
,wtT 
acpS 
g1655674 
g1655675 
g1657365 
g1657366 
g1657367 
g1657368 
g1657369 
92078020 
g2078021 
92078022 
92624316 
92791425 
*Molecular weight predicted using the program EditSeq version 3.92. +PID, protein identification number given by the NCBI. *Protein and gene 
name assigned in the M. tuberculosis H37Rv genome is given in parenthesis [201. 
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Figure 4 
Conservation of core motifs from peptide 
synthetases and polyketide synthases in the 
proteins MbtB, MbtC, MbtD, MbtE and MbtF. 
The core sequences for (a) adenylation, 
(b) condensation, (c) cyclization, 
(d) epimerization and (f) thioesterase 
domains, as well as the conserved sequence 
at the (g) carrier protein domains are defined 
according to those reviewed by Marahiel and 
coworkers [22] and are red in each box. 
(e) The ketoacyl-ACP-synthase (KS), 
acyltransferase (AT), and ketoreductase (KR) 
core signatures are defined as in Donadio et 
al. [40], and are red. The numbers at the far 
left end of the sequence in parentheses 
indicate the position of the first amino acid in 
the adjacent core, whereas the numbers 
between the cores represent the number of 
amino acids separating the adjacent cores. 
The letter ‘x’ and its subscript represent 
positions and number of amino acids, 
respectively, where conservation is not 
observed. 
(c) Cyclization domain from MbtB 
*tB-Cy 49 IPXVFTSXL) 18 (Wx,Qx,QV~,~x,~x,Gx,~) 
(d) Epimerization domain from MbtF 
(e) Ketoacyl-ACP-synthase (KS), Acyltranferase (AT) and ketoreductase (KR) domains 
from MbtC and MbtD 
.AT core KS c’Jre GESxG GPX5TACSS 
M&D-AT 189 CGHSXG) *nrc-KS 167 ~GPX5TSCSS) 
(g) Phosphopantethenylation sites 
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noted elsewhere [24,2.5] that such consensus sequences or acyl-transferase domain in MbtB. Although MbtB con- 
can be subdivided into PCP, ArCP and acyl carrier tains the two core sequences for a thioesterase domain at 
protein (ACP) sites, and on that basis (as well as on a con- its carboxyl terminus, the two domains share characteris- 
textual basis) designated the two MbtB sites as ArCP and tic motifs, and the first of these also corresponds to an 
PCP sites, the two MbtD sites as ACP sites, and the acyl-transferase domain. Either the thioesterase or the 
remaining three MbtE and MbtF sites as PCP sites. By acyl-transferase domain would be a candidate for assisting 
this measure MbtC and MbtD would be polyketide syn- in the transfer of intermediates from MbtB to ACPl in 
thase components, as borne out by their additional MbtD. Of particular note is a variant condensation 
homology to ketoacyl-ACP synthase domains (MbtC) and domain in MbtB that is homologous to the thiazoline-het- 
to ketoreductase and acyl-transferase domains (MbtD). erocyclizing domains in the yersiniabactin and bacitracin 
Additional domains with related functional significance synthetases [Zl] (Figure 4~). This strongly suggests that 
are an epimerization domain in MbtF, and a thioesterase MbtB starts with an ArCP domain, which is followed by 
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Figure 5 
(a) 
(a) Alignment of the salicyl-AMP ligase MbtA 
and its f. co/i and Y. pestis homologs, EntE 
and YbtE. (b) Alignment of the PPTases from 
hl: tuberculosis, PptT, and f. co/i, EntD. In 
(a) and (b) identical amino acids between the 
mycobacterial proteins and their homologs are 
indicated in red. In (b) the residues comprising 
the conserved PPTase signature motif [17,31] 
are underlined. Cc) Alignment of 1111 tuberculosis 
MbtH, and its homologs. Identical residues 
present in four of the seven aligned proteins 
are indicated in red. ORFms was deduced from 
a reported 4261 bp fragment from 
M. smegmafis (nucleotides 3925-4119, 
accession number U10425). ORFl is located 
in the E. co/i enterobactin gene cluster 
(accession number JO421 6). ORFec was 
deduced from a reported 2023 bp fragment 
from E chrysanfhemi (nucleotides 
1600-l 755, accession number AFOl1334). 
ORFbs was deduced from the complement 
strand of the reported 217420 bp fragment 
(section 17 of 21) from B. subtilis complete 
genome (nucleotides 82354-82560, 
accession number AL0091 26). ORF6 is 
located in the chloroeremomycin gene from 
Amycolatopsos orientalis (accession number 
AJ223999). ORFmx was deduced from the 
complement strand of a reported 1610 bp 
fragment from M. xanfbus (nucleotides 
192-407, accession number D50555). See 
text for references and more details. 
an oxazoline-forming domain, as anticipated for initiation 
of mycobactin assembly. 
Mbtl has homology to a family of isochorismate synthase, 
anthranilate synthase and salicylate-forming enzymes, con- 
sistent with a role in the conversion of chorismate to salicy- 
late, the starter unit for mycobactin siderophore 
construction. MbtJ has homology to an acetyl hydrolase and 
MbtG has homology to ornithine and lysine N-oxygenases, 
activities that would be required for N-hydroxylation of the 
two lysine residues at some stage during mycobactin assem- 
bly. All these analyses suggest that this set of nine ORFs 
forms the core of the mycobactin synthetase gene cluster. 
MbtH as yet has no function assigned; MbtH homologs are 
found in several gene clusters for biosynthesis or transport 
of siderophores and other nonribosomally synthesized pep- 
tides, however (Figure 5c) [26-281. 
Additionally, in order for the complex to be active, each of 
the seven predicted carrier protein domains of MbtB, 
MbtD, MbtE and MbtF must be activated (from apo to 
holo forms) by post-translational phosphopantetheinylation 
at the consensus serine residue in each domain (Figure 4g). 
Prior studies in our group identified two subtypes of 
PPTases, one specific for apo ACP domains in fatty acid 
and polyketide synthases, and the second specific for modi- 
fication of apo-PCP and apo-ArCP domains in peptide syn- 
thetases [25]. Using E. co/i AcpS [29] as a model for the 
ACP-specific PPTase and E. coli EntD [17] as a model for 
the ArCP- and PCP-specific PPTase, we detected two 
mycobacterial homologs in the M. tubercdosis genome 
(Table 1). One of these homologs (which is 33% similar to 
E. coli AcpS) was designated as mycobacterial AcpS in the 
recently published genome sequence of M. tuberculosis 
strain H37Rv [ZO]. The second homolog had similarity to 
EntD (30%, Figure 5b) and we now designate this gene 
product PptT. In agreement with the 14 kDa and 26 kDa 
masses of E. coli AcpS and E. co/i EntD, respectively, the 
mycobacterial AcpS is a 14 kDa protein and PptT is a 
25 kDa species. Neither the mycobacterial acpS nor pptT 
maps near the mbt gene cluster. The acpS gene is immedi- 
ately downstream of a large ORF likely to be a fatty acid 
synthase subunit, consistent with an ACP-selective post- 
translational function of AcpS. In nonribosomally synthe- 
sized peptide biogenesis, PPTase genes are usually found 
in the proximity of the genes encoding their targets; analy- 
sis of the ORFs around pptT is not particularly revealing 
with respect to possible PptT targets, however. We 
decided, based on homology, that PptT was the more 
likely of the two to catalyze the phosphopantetheinylation 
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Figure 6 
(a) MBP fusions of mycobacterial proteins 
overproduced in and purified from E. co/i in 
this study. The mycobacterial portion of the 
fusion proteins released after proteolytic 
cleavage at the thrombin cleavage site (TCS) 
and purified are indicated in (b). The fusions 
included a histidine tag (H6) at the carboxyl 
terminus, except for the PptT construct. TCS’ 
indicates a portion of the TCS remaining on 
the mycobacterial proteins. The PptT used for 
enzymatic characterization was the uncleaved 
MBP fusion (see text for details). 
(a) 
MBP-ArCP-H6 
MBP-PCPS-H6 
MBP-PptT 
MBP-MbtA-H6 
6 
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of the ArCP initiator domain and PCP domains involved in 
mycobactin biosynthesis. 
Overproduction of PptT, MbtA and the carrier protein 
domains of MbtB and MbtE in E. co/i 
constructs contained hexahistidine tags (His or H6) at 
their carboxyl termini. In every case the His-tagged con- 
structs of these mycobacterial proteins were expressed 
very poorly or undetectably in E. coli. 
As an initial test to validate assignment of the mbt genes We next turned to in-frame fusions with maltose-binding 
to the mycobactin synthetase, we tested the proposed ini- protein (MBP); we hoped this strategy would permit 
tiation functions of the complex (Figure Za). To this end expression and accumulation of the mbt proteins in E. co& 
we overproduced and purified the proposed substrate but had success with only MBP-ArCP (MbtBl-88)-H6, 
ArCP domain (the amino terminus of MbtB), the pro- MBP-PCP3 (MbtE1570-1658)-H6, MBP-PptT and 
posed PPTase (PptT) that would convert the inactive MBP-MbtA-H6 (Figure 6). The carboxy-terminal His tags 
apo-ArCP to its active holo form, and the proposed salicy- were maintained in the fusion proteins to facilitate purifica- 
late-activating enzyme (MbtA). The genespptT, v&A and tion after cleavage of the MBP tag. All the overproduced 
the 5’ 4rCP region of m&B (300 base pairs, bp) were thus constructs were substantially insoluble when overproduced 
cloned from M. tuberc&osis CSU93. We also cloned the at 37°C but were soluble when induced at 24°C. We were 
remaining six predicted PCP and ACP domains from able to cleave and purify the ArCP and PCP3 fragments 
MbtB, MbtD, MbtE and MbtF. Our initial expression (Figure 7) for use as apo substrates. The final yields of the 
Figure 7 
Levels of overproduction and purity of the 
mycobacterial recombinant substrates 
(a,b) ArCP and (c,d) PCP3, and the enzymes 
(e) PptT and (f) MbtA used in this study. 
Lanes 1 and 2 were loaded with cell lysate 
from uninduced and induced cultures of the 
E. co/i strains BL21 (DES)/pARCP (a), 
BL21 (DES)pLysS/pPCPS (c), BL21 (DE3)/ 
pPptT (e), and BL21 (DES)pLysS/pMBTA (f). 
Lane 3 (a,c,e,f) and lane 1 (b,d) were loaded 
with the corresponding MBP fusion proteins 
purified on amylose resin. In lane 2 of (b,d), 
and lane 4 of (f), the thrombin-digested MBP 
fusions were loaded, and the final 
mycobacterial proteins purified by Ni-affinity 
chromatography were loaded in lane 3 (b,d) 
or lane 5 (f). Protein samples were resolved 
by 10% Tris-Glycine (a,c,e,f) or 160/o Tris- 
Tricine (b,d) SDS-PAGE. M, molecular 
weight markers. 
a) M 1 2 3 (b) M 1 2 3 (c) M 1 2 3 
00.0 66.2 200.0 
16.0 45.0 ’ 97.4 31 ii;:: 
66.2 
21.5 66.2 
45.0 
14.4 45.0 
6.5 31.0 
31.0 
d) M 1 2 3 (e) M 1 2 3 if\ Ml2345 , , 
200.0 
116.0 
97.4 
66.2 
116.0 
97.4 
66.2 
21.5 
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Figure 8 
Demonstration of PptT-dependent 
phosphopantetheinylation and MbtA- 
dependent acylation of ArCP and PCP3. 
(a,c,e) Coomassie-stained 160/o Tris-tricine 
gels of phosphopantetheinylation reactions, 
MbtA-catalyzed acylation reactions and EntE 
and YbtE-catalyzed acylation reactions, 
respectively. (b,d,f) The corresponding 
autoradiographs for (a,c,e), respectively. Gels 
were stained, soaked in Amplify (Amersham) 
for 30 min, and exposed to film for 1 week. 
Phosphopantetheinylation reactions (100 pl, 
incubated at 37°C for 3 h) contained the apo- 
substrates (5 yM), [3HlCoA (80 PM), and 
PptT (200 nM). Lanes l-6 of the gel in (a,b) 
were loaded with 30 ~1 of the reaction 
mixtures containing the MBP-ArCP, thrombin 
cleaved MBP-ArCP (partial digestion 
following reaction), purified ArCP-H6, 
MBP-PCPS, thrombin cleaved MBP-PCP3 
(partial digestion), and purified PCP3-H6 
respectively. Arylation reactions were 
performed using [14C]salicylic acid as 
described in the Materials and methods 
section. Lanes l-4 of the gel in (cd) were 
loaded with the MbtA-catalyzed salicylation 
reaction mixtures containing the MBP-ArCP, 
thrombin cleaved MBP-ArCP (partial 
digestion following reaction), purified ArCP- 
H6, and purified PCP3-H6, respectively. 
Lanes 1 and 3 of the gel in panels e and f 
were loaded with the EntE-catalyzed L 
(a) 
~~:“; 
45.0 
31 .o 
21.5 
14.4 
6.5 
Ml 2345 6 M (b) M 1 2 3 4 5 6 M 
w M1234M W M 1 2 3 4 M 
’ 7067:oo 
52.0 
36.8 
:;:: 
6s) Ml2 3 4M (f) M 1 2 3 4 M 
97.4 
66.2 
45.0 
21.5 
14.4 
6.5 
Chemistry & Biology 
salicylation reaction mixtures containing ArCP- of this gel were loaded with the YbtE- containing ArCP-H6 and PCP3-H6, 
H6 and PCP3-H6 respectively; lanes 2 and 4 catalyzed salicylation reaction mixture respectively. M, molecular weight markers. 
purified, cleaved proteins were 10 mgll for ArCP and 
3.5 mgll for PCP3. We were also able to cleave MBP-PptT, 
but the resultant PptT-H6 protein did not bind well to 
nickel columns; furthermore, PptT-H6 and the fusion 
protein were both inactive. Re-expression of the PptT con- 
struct without the His-tag rendered a phosphopantetheiny- 
lation-competent MBP-PptT fusion; cleavage of the MBP 
portion released PptT as an inactive protein, however. 
Attempts to optimize cleavage conditions did not solve the 
problem, so we decided to use PptT as an MBP fusion 
(Figure 7e). The final yield of the purified MBP-PptT was 
35 mgll. The MBP-MbtA-H6 fusion expressed poorly. 
Both the MBP fusion and the MbtA protein purified after 
cleavage were active and the cleaved MbtA-H6 was used 
for enzymatic characterization (Figure 6). The final yield of 
the purified, cleaved MbtA-H6 was 0.1 mgll. 
Characterization of MBT-PptT as a phosphopantetheinyl 
transferase 
The PPTase activity of PptT was validated using tritiated 
coenzyme A (CoA) and assaying for covalent incorporation 
of [3H]-P-pant [17] into the apo-ArCP and apo-PCP3 sub- 
strates. The MBP fusions of both the MbtB ArCP domain 
and the MbtE PCP3 domain were labeled (Figure 8). 
These results also prove that the two apo carrier protein 
fragments from MbtB and MbtE are PptT substrates. The 
conversion of apo to holo forms was also validated by alter- 
ations in high-performance liquid chromatography (HPLC) 
migration (Figure 9a) and mass spectrometry, which 
showed a mass increase of 338 Da for holo ArCP and 
353 Da for holo PCP3, in correspondence with the 340 Da 
increase in mass expected for the incorporation of the 
P-pant group (Table 2). As shown in Figure 9b the amount 
of label incorporated into 2.5 FM apo-PCP3 and 5 PM apo- 
ArCP plateaued with time, and, as expected, there was 
twice as much radioactivity in the doubly concentrated 
ArCP. The HPLC and mass spectrometry data above indi- 
cate quantitative conversion of apo to holo forms of the 
carrier protein fragments and the assumption that the 
plateaus represent stoichiometric modification allowed us 
to calibrate the tritium-specific radioactivity and concentra- 
tion of the holo forms of PCP3 and ArCP. This calibration 
was used to obtain the KM and k,,, values in the PptT- and 
Mb&dependent reactions with the cleaved ArCP and 
PCP3 apo fragments, shown in Table 3. 
The concentration-dependent covalent incorporation of a 
[3H]-P-pant group into either the apo-ArCP or apo-PCP3 
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(a) HPLC traces of apo and holo forms of PCP3 and ArCP and (b) time 
course of apo to holo conversion of PCP3 and ArCP. Coinjection of 
apo and holo forms of PCP3 showed two distinct peaks (data not 
shown). Carrier proteins were phosphopantetheinylated in reactions 
containing 50 FM of apo substrate, 200 yM of unlabeled CoA and 
500 nM PptT. Reactions were incubated at 37°C for 6 h before 
injecting 5-l 5 ug of carrier protein for HPLC separation, DTT was 
added (20 mM) to the ArCP samples just before being injected into the 
HPLC. In (b) the carrier proteins were phosphopantetheinylated in 
reactions containing the apo substrate (2.5 PM PCP3 or 5.0 uM ArCP), 
80 FM 13HlCoA and 500 nM PPtT (ArCP reactions) or 100 nM PptT 
(PCP3 reactions). Incorporation of tritium label in holo proteins was 
determined by radioassay. Closed circles represent ArCP time points, 
open circles represent PCP3 time points. 
(Figure 10) shows substantial to dramatic substrate inhibi- 
tion above 2.5 /L-M and 10’pM substrate, respectively, in 
incubation mixtures of low ionic strength, making the KM 
and kc,,, values very difficult to determine accurately. We 
have seen such potent substrate inhibition by apo carrier 
proteins towards other PPTases - most notably, the ACP- 
specific AcpS of E. coli’ [29] and the ArCP-specific EntD of 
E. coli [30] are inhibited by apo ACP and apo ArCP, respec- 
tively. Much of the inhibition is suppressed in high salt, 
however. Similarly, as shown in Figure 10, 500 mM NaCl 
(in the ArCP reaction) or 750 mM NaCl (in the PCP3 reac- 
tion) allowed determination of steady-state kinetic parame- 
ters. The plots of velocity as a function of CoA 
concentration (data not shown) did not show this pro- 
nounced substrate inhibition and a K,, value of 1 PM for 
Table 2 
Mass spectral data demonstrating modification 
(phosphopantetheinylation) of ArCP and PCPS. 
ArCP 
PCP3 
Mass observed Mass increase 
Apo form Holo form Observed Predicted 
10821 11159 338 340 
11473 11826 353 340 
CoA was determined with apo-ArCP as P-pant acceptor. 
The KM values of 6 PM for apo ArCP and 12 /.I.M for apo 
PCP3 suggest equivalent and robust recognition of these 
carrier protein domains by PptT. The I,?~,,, values of 2 min-l 
for covalent priming of carrier proteins are in the range seen 
for the enterobactin-specific PPTase EntD (7 min-r [30]) 
working on its cognate substrate (apo-ArCP of EntB) or on 
the yersiniabactin apo-ArCP from the amino terminus of 
HMWPZ (1.5 min-1 [16]), but are an order of magnitude 
lower than the kcEt values of the surfactin-specific PCP mod- 
ifying PPTase Sfp acting on two of its apo-PCP domains 
(SO-100 min-r [31]). PptT also recognized the heterologous 
carboxy-terminal apo-ArCP fragment of E. co,2 EntB as a 
substrate for phosphopantetheinyl transfer (Table 3). 
Characterization of MbtA as a salicyl-AMP ligase and a 
salicyl-S-ArCP synthetase 
MbtA was demonstrated to activate the mycobactin ArCP 
in two half-reactions. The first half-reaction, activating sali- 
cylic acid as the corresponding acyladenylate, was con- 
firmed using the classic ATP-[32P]PPi exchange assay. The 
kinetic parameters for the adenylation reaction were also 
determined. The K,v value of 9.0 /tM for salicylic acid is 
comparable to the KM of 2.7 FM determined for EntE, the 
corresponding 2,3-dihydroxybenzoyl-AMP ligase involved 
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Table 3 
Kinetic parameters for phosphopantetheinylation catalyzed by MBP-PptT. 
ArCP-HGt 
PCP3-H6 
EntB-ArCP* 
CoA§ 
No NaCl added* NaCl added 
k,, (min-I) &,, (PM) 4 (PM) k,,, (mini) K,,, (PM) k,lK, (PM) 
2 7 14 2 6 0.33 
>l >l <1 2 12 0.16 
1 1 19 nd nd nd 
nd nd nd 1 1 1 
*Substrate inhibition was observed without addition of NaCl to the 
reactions. Inhibition was particularly severe with PCP3-H6, resulting in 
an unacceptable error in the calculation of kinetic parameters even 
using the substrate inhibition equation 1361. Addition of NaCl (250 mM 
for ArCP-H6 reactions and 750 mM for PCP3-H6 reactions) reduced 
the substrate inhibition, and the kinetic parameters were calculated 
using the Michaelis-Menten equation. +Reactions to obtain kinetic 
parameters for the carrier proteins as substrates contained: 13HJCoA 
([3H]phosphopantetheine specific activity 36 Ci/mol) at 82 uM and 
in E. coli enterobactin biosynthesis [‘23]. The kc,,, of 
42.7 min-’ for MbtA is somewhat lower than the turnover 
number of 340 min-1 found previously for EntE. 
The second half-reaction, transfer of activated salicylate to 
the MbtB ArCP as a thioester, was investigated by arylating 
the holo ArCP (formed by the PptT-catalyzed reaction with 
CoA) using [14C]salicylate as the substrate. Trichloroacetic 
acid precipitation of protein following exhaustive labeling 
using MbtA or EntE indicated modification stoichiometries 
of about 27% and 63%, respectively, suggesting that either 
of these enzymes could serve as catalysts for the transfer. 
Incorporation of the salicyl group into the holo ArCP sub- 
strate was also validated using mass spectrometry; a mass 
increase of 1’23 Da over the mass of the holo ArCP 
Figure 10 
MBP-PptT at 25 nM (ArCP-H6 and EntB-ArCP containing reactions) 
or 55 nM (PCP3-H6 containing reactions). *Substrate inhibition was 
also observed with the heterologous EntB-ArCP substrate, a carboxy- 
terminal His-tagged ArCP fragment from E. co/i EntB (residues 
188-285). EntB-ArCP also produces similar inhibition of 
phosphopantetheinylation reactions using its cognate PPTase, EntD 
[25]. SReaction to obtain kinetic parameters for CoA contained 
MBP-PptT at 25 nM and ArCP-H6 at 15 FM. nd, not determined. 
(11159 Da, Table 2) for the salicylated carrier protein was 
observed, in agreement with the predicted mass increase of 
120 Da. The autoradiograph shown in Figure 8d indicates 
the Mb&catalyzed covalent labeling of the MBP- 
ArCP-H6 fusion with [14C]Sal (lane 1). Cleavage of the 
MBP tag from this fusion protein following the labeling 
reaction (lane 2) demonstrates that the label is within the 
ArCP portion of the protein. Surprisingly, no significant 
labeling of the purified, cleaved ArCP-H6 was observed 
using MbtA (lane 3), suggesting that cleavage of the MBP 
tag from this protein substrate could cause a conformational 
change that inhibits proper protein-protein interaction from 
occurring. Finally, as expected, no labeling of the 
MBP-PCP3-H6 (data not shown) or purified cleaved 
PCP3-H6 (lane 4) was observed using MbtA. 
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PptT-dependent phosphopantetheinyl transfer 
to apo ArCP and apo PCPB. (a-d) Plots 
show the phosphopantetheinylation reaction 
velocity as a function of (a,b) apo-ArCP and 
(cd) apo-PCP3 concentration, respectively. 
Reaction mixtures including the apo protein 
and 80 uM [3H]CoA were incubated at 37°C 
for 30 min with 25 nM PptT (ArCP reactions) 
or 55 nM PptT (PCP3 reactions). NaCl was 
added (500 mM in ArCP reactions and 
750 mM in PCP3 reactions) to reduce 
substrate inhibition and obtain the data shown 
in (b,d). Note the difference in scale of the 
x axis in plots (b,d). PPTase activity was 
measured by monitoring incorporation of 
[3H]P-pant into apo substrate by radioassay. 
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The specificity of the salicyl-transfer reaction was investi- 
gated using the heterologous aryl-AMP ligases EntE (from 
E. co& and YbtE (from I’. pest;S). The autoradiograph in 
Figure 8f clearly demonstrates that these ligases are able to 
transfer salicylate to the mycobacterial ArCP-H6 domain 
but not to the PCP3-H6 fragment. The clear specificity of 
MbtA, EntE and YbtE for aryl, and not peptidyl carrier 
protein domains as acylation substrates further emphasizes 
the ability of peptide and siderophore synthetases to distin- 
guish between these two types of domains. 
Discussion 
Because the virulence-conferring mycobactins of the slow- 
growing pathogenic mycobacteria (M. tzlberculosis and 
M. a&m) have sufficient structural homology to other 
siderophores (Figure 1) they probably arose through a 
common biosynthetic strategy using comparable nonribo- 
somal peptide synthetase catalytic logic. In particular, the 
unusual hydroxyphenyl-thiazoline ring of yersiniabactin 
and the hydroxyphenyl-oxazoline ring of the mycobactins, 
thought to contribute two of the six coordinating ligands to 
ferric iron, reflects an essentially identical start to these 
nonribosomally synthesized peptides (Figure Zc,d). We 
recently deconvoluted the enzymatic strategy and multido- 
mainal organization of the seven-domain HMWPZ of 
yersiniabactin synthetase [16], as well as that of the enter- 
obactin synthetase of E. coli [18]. The key feature of both 
these strategies is that siderophore chain assembly begins 
with the formation of an aryl-S-ArCP-enzyme intermedi- 
ate. This species serves as the acyl donor in the first amide 
bond forming step to the first amino acid covalently teth- 
ered in similar acylthioester linkage at the next down- 
stream carrier protein domain (serine for enterobactin, 
serine or threonine for mycobactins and cysteine for 
yersiniabactin; Figure Zc,d). The a&N-capping of the first 
amino acid is functionally equivalent to N-formylation of 
the first methionine in bacterial ribosomal protein synthe- 
sis. In yersiniabactin (and probably mycobactin) assembly 
the Sal-Cys-S-enzyme or Sal-Ser-S-enzyme intermediates 
are dehydratively cyclized prior to the next amide bond 
formation step, effected by a variant condensation domain 
termed a cyclization domain. Such cyclization domains 
have core motifs that distinguish them from normal con- 
densation domains of peptide synthetases and have now 
been found in bacitracin synthetase [Zl], three times in the 
three ring-forming yersiniabactin synthetase [ 161, and 
noted here for MbtB (Figure 4~). 
Rationalizing that mycobactin synthesis involves an aryla- 
tion-heterocyclization initiation strategy, and given that 
peptide synthetase and polyketide synthase genes are typ- 
ically clustered, we scanned the M. fuberculosis genome for 
a candidate gene cluster for the mycobactin synthetase 
and identified ten ORFs m&A-J that have the appropriate 
hallmarks. Some of these genes were recently suggested 
to be involved in mycobactin biosynthesis by Cole et a~‘. 
[ZO]. It is probable that MbtB is the peptide synthetase on 
which chain growth is initiated, given that the two most 
proximal domains are ArCP and heterocyclization 
domains. The other two peptide synthetase homologs 
MbtE and MbtF, each with a single amino-acid adenyla- 
tion domain, probably activate the two lysine residues that 
are incorporated into mycobactin, but it is not yet clear in 
what order they function, nor is it clear whether lysine or 
&-N-hydroxylysine (from action of MbtG on the free 
amino acid) is the substrate. Clarification of these issues 
awaits successful expression of functional adenylation 
domains or full-length MbtE and MbtF, not yet achieved 
in E. coli despite several attempts. 
The cyclic N-hydroxylysine terminus in the siderophore 
probably arises by intramolecular lactamization to release 
the completed siderophore chain from its last PCP waysta- 
tion (PCP3 or PCP4). The similarity of epimerization 
domains to condensation domains suggests that the 
epimerase assigned to the carboxyl terminus of MbtF 
might be involved in the lactamization of the lysine 
residue, which involves intramolecular formation of a 
peptide bond with concomitant product release. The MbtC 
and MbtD proteins contain polyketide synthase hallmarks 
consistent with the fact that mycobactins appear to be 
mixed nonribosomal peptide/polyketide natural products. 
The 3-hydroxybutyrate spacer between the two hydroxy- 
lysine residues of mycobactin could arise from typical 
polyketide-synthase-mediated Claisen condensation bio- 
chemistry from acyl CoA starter units carried on the phos- 
phopantetheinylated ACP domains of MbtD. The only 
catalytic activity not clearly discernible in the cluster is the 
fatty-acyl transferase activity that transfers both the long 
chain acyl groups (to membrane-bound mycobactins) and 
the short acyl chain fragments (to soluble carboxymy- 
cobactins) to the internal N-hydroxylysine sidechain. It is 
possible that MbtJ is such an acyl transferase or that 
M. tuberczGlosis could use one of many other acyl transferases 
from its extensive lipid synthesis inventory [ZO]. Only one 
other peptide synthetase gene (nrp) is present in the 
M. tzlberczllosis genome [ZO], at a locus distinct from the mbt 
cluster. Our analysis of the nrp gene product tentatively 
suggests the domain organization adenylation-PCP-con- 
densation-adenylation-PCP; nrp lacks a cyclization domain. 
Given that this domain organization does not match the 
one predicted for mycobactin assembly, it is unlikely that 
this gene is involved in.mycobactin biosynthesis. 
These assignments parallel the recent suggestion of Cole et 
al. [ZO] from the genome sequencing of M. tubemdosis 
H37Rv. Although there appear to be at least four clusters 
of polyketide synthase genes and about 250 ORFs 
involved in fatty acid metabolism, Cole et al. [ZO] also 
detected an isolated ORF (nrp) and the cluster of peptide 
synthetase genes that they and we designated mbt. The 
clinical isolate M. tzLberculosis CSU93, from which the genes 
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expressed in this work have been cloned, has the same mbt 
gene organization as the M. tu~ercz~losis H37Rv strain. 
As an initial effort to .test this molecular biosynthetic organi- 
zation and catalytic strategy for mycobactin synthesis by 
M. &her-culosis, we cloned, expressed, purified and assayed 
the three proteins required for the initiation of mycobactin 
synthesis (shown in Figure ‘Za). Unfortunately, the protein 
biochemistry and enzymology have been plagued by uni- 
formly poor to nonexistent expression/accumulation of both 
fragment and full-length forms of MbtA, MbtB, MbtD, 
MbtE and MbtF, as well as PptT. Although the MBP- 
fusion strategy ultimately prevailed for the ArCP, PCPS, 
PptT and MbtA constructs needed in this study, we were 
unable to express many of the other fragments in E. coli. 
The other proteins might have to be expressed in fast 
growing, nonpathogenic mycobacterial strains, such as 
M. smegmutis, to produce active proteins in useful quantities. 
Even though the apo forms of M. tz&ercuZososis ArCP and 
PCP3 are activated by the E. coli EntD [30] and B. subtikis 
PPTases [31] in vitro (data not shown), we searched for 
and found two M. tuberctilosis candidate PPTases. They 
fall into the size and homology categories previously 
noted for fatty acid and polyketide biosynthetic PPTases 
(AcpS) and nonribosomal peptide biosynthetic PPTases 
[ZS]. On that basis we cloned, expressed and purified 
PptT, and validated its ability to post-translationally 
prime the apo ArCP and PCP3 fragments with P-pant. 
This is the likely physiological role of PptT, and PptT 
probably activates at least the five serine sidechains of the 
carrier protein domains in MbtB, MbtE and MbtF 
(Figure 3b). Presumably, M. tuberculosis AcpS primes the 
MbtD apo-ACP domains, but experimental proof awaits 
successful expression of both the apo-ACP domains and 
the M. tuberculosis AcpS MbtD. 
Because MbtA has extensive homology to both E. coli 
EntE (2,3-dihydroxybenzoyl-AMP ligase) [30] and YbtE 
(salicyl-AMP ligase) [16], it is the prime candidate for the 
salicyl-AMP ligase and arylating enzyme at the initiation of 
mycobactin chain growth, and that expectation is borne 
out. Not only does MbtA show the salicylate-dependent 
ATP-[32P]PPi exchange characteristic of reversible Sal- 
AMP formation in its active site, but it is also able to acylate 
the holo form of the amino-terminal ArCP fragment of 
MbtB (Figure 8d) and produce the Sal-S-ArCP that repre- 
sents the first committed covalent acyl-enzyme intermedi- 
ate in mycobactin chain growth (Figure Za). As a caveat, it 
is worth noting the relative inefficiency of the MbtA-cat- 
alyzed transfer of salicylate to the ArCP fragment, a 
reminder of the difficulty in working with arbitrarily chosen 
fragments of larger synthetase domains. 
In summary, this study has focused on the ten-gene 
cluster of M. tuberczldosis involved in the biogenesis of the 
hydroxyphenyloxazoline-containing siderophore myco- 
bactins required for growth of these pathogenic bacteria in 
extracellular sites in vertebrate hosts. Four of the proteins 
encoded in this cluster or protein fragments thereof have 
been expressed in and purified from E. coLi and validated 
for their predicted function. The mycobactin biosynthetic 
strategy conforms to an initiation sequence involving post- 
translational priming of peptide synthetase amino-terminal 
ArCP domain, aryW-capping of the growing peptide chain, 
and heterocyclization of a serine or threonine sidechain to 
the iron-ligating oxazoline moiety. All three of these enzy- 
matic steps, phosphopantetheinylation, arylation and hete- 
rocyclization, should be amenable to selective inhibitor 
design, which could reduce or abrogate pathogenicity and 
virulence in mycobacterial, yersinial, and many other bacte- 
rial infections. In this connection, a mycobacterial ACP, 
AcpM, acting as a carrier protein in the mycolic-acid bio- 
genesis pathway, has recently been identified as the target 
of the clinical antitubercular drug isoniazid [32]. 
Significance 
Mycobactins are iron-chelating molecules synthesized by 
a variety of Mycobacterium species. Although these vir- 
ulence-conferring siderophores were first isolated more 
than 30 years ago, the mechanism of their biosynthesis 
has remained opaque. This work identifies the gene 
cluster in M. tuberculosis responsible for mycobactin 
synthesis. The cluster encodes a mixed polyketide syn- 
thase/nonribosomal peptide synthetase system, and is 
similar to the peptide synthetase systems of other bacter- 
ial siderophores, such as yersiniabactin from the plague 
bacterium Yersinia pestis. 
In addition to reporting the organization of the 
mycobactin gene cluster, we have demonstrated the initi- 
ation steps in mycobactin biosynthesis. Four of the pro- 
teins or protein fragments from the cluster have been 
expressed and purified in Escherichia coli and have been 
validated for their predicted function. We have reconsti- 
tuted the phosphopantetheinylation of the N-terminal 
aryl carrier protein and a downstream peptidyl carrier 
protein, and demonstrated loading of salicylate onto the 
aryl carrier protein. These two enzymatic steps, phos- 
phopantetheinylation and arylation, as well as other 
steps to be elucidated in the future, should prove excel- 
lent targets for selective inhibitor design that could com- 
plement current treatments for tubercular infections. 
Materials and methods 
Materials and recombinant DNA techniques 
Luria-Bertani (LB) medium was prepared and used for culturing E. co/i 
strains as described previously [33j. Competent cells of f. co/j strains 
DHSrx. BL21 (DE3). and BL21 (DE3)pLvsS were purchased from Gibco- 
BRL and Novagen’respectively. Restriction endonucleases and T4 DNA 
ligase were obtained from New England Biolabs. Plasmid plADLl4 
expressing maltose binding protein (MBP) fused to the amino terminus of 
VanX has been described elsewhere [34]. Thrombin endoprotease was 
purchased from Novagen, and proteolytic cleavage was performed as 
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recommended by the supplier. The proteins EntB-ArCP-H6, EntE and 
YbtE [16,30] were kindly provided by Amy M. Gehring. Unlabeled coen- 
zyme A (GoA) was purchased from Sigma. L3HlCoA (-70% label in 
phosphopantetheinyl moiety as determined by previously described 
methods 1351) was prepared by DuPont New England Nuclear. L3HlCoA 
was acetylated and purified as previously described [351. Genomic DNA 
from h/l. tuberculosis strain CSU93 was kindly provided by John T. 
Belisle (Colorado State University). This strain is a clinical isolate whose 
genome is being sequenced by TIGR. Recombinant DNA techniques 
were performed as described previously [331. Plasmid DNA preparation, 
gel extraction of DNA fragments, and purification of DNA amplified by 
polymerase chain reaction (PCR) were performed using alAprep@, 
QIAEX@ II, and QIAquick@ kits, respectively (Qiagen). PCRs were 
carried out using Pfu DNA polymerase as described by the enzyme sup- 
plier (Stratagene), except for the addition of DMSO (10%) and glycerol 
(3%) to the mixtures. The fidelity of PCR-amplified DNA fragments was 
established by nucleotide sequencing after subcloning into the corre- 
sponding expression vector. DNA sequencing was performed on double- 
stranded DNA by the Molecular Biology Core Facility of the Dana Farber 
Cancer Institute (Boston, MA). Oligonucleotide primers were obtained 
from Integrated DNA Technology Inc. and are listed in Table 4. 
using amylose resin according to the manufacturer’s instructions (New 
England Biolabs). Fractions of the eluant from the amylose column were 
analyzed for the presence of the fusion proteins by SDS-PAGE. Frac- 
tions containing the PptT fusion were pooled and dialyzed against 
10 mM Tris-HCI (pH 8.0), 1 mM EDTA, 1 mM DTT, 100 mM NaCI, and 
5% glycerol (Buffer A). After dialysis, the fractions were aliquotted, flash 
frozen in liquid nitrogen, and stored at -80°C. 
Cloning, overproduction and purification of MBP-PptT and MbtA 
The pptT and the m&4 genes were amplified from M, tuberculosis 
CSU93 genomic DNA using the primers LQ-131 and LQ-132 CoptT), 
and LO-1 26 and La-1 54 (mbtA), respectively. The amplified pptT and 
mbtA fragments were digested with Ndel and b’indlll, gel-purified and 
ligated to the 5192 bp vector backbone (obtained from lVdel/Hindlll 
digestion of plasmid plADL14) to generate the plasmids pPptT and 
pMBTA, respectively. The pPptT plasmid expresses a translational fusion 
(MBP-PptT protein) resulting from the joining of the MBP fragment 
encoded in plADLl4 and the 227-residue PptT PPTase. The plasmid 
pMBTA expresses a translational fusion (MBP-MbtA-H6 protein) in 
which the MBP fragment and the His-tag fragment encoded in the vector 
are fused in frame to the amino and carboxyl termini, respectively, of the 
565 residue MbtA salicyl-AMP ligase. The fusion constructs are outlined 
in Figure 6. pMBTA and pPptT were introduced by transformation into 
E. co/i strain DH5a, and then pPptT was transferred to the E. co/i strain 
BL21 (DE3) and pMBTA to the strain BL21 (DE3)pLysS for expression 
and overproduction of the fusion proteins. 
Fractions containing the MbtA fusion were pooled and CaCI, was 
added to 2.5 mM. The fusion protein was cleaved with thrombin endo- 
protease at the cleavage site placed between MBP and MbtA-H6. When 
cleavage was complete (assayed using SDS-PAGE), benzamidine was 
added (1 mM) to inhibit thrombin. Cleavage releases the MbtA-H6 fusion 
(MbtA plus the vector-derived Gly-Ser-His fragment and the His tag at 
the amino and carboxyl termini, respectively). After addition of benzami- 
dine, NaCl and imidazole were added to the cleavage reaction mixture to 
final concentrations of 250 mM and 2.5 mM, respectively, and the 
carboxy-terminal His-tagged MbtA-H6 fusion was purified by nickel 
column chromatography using His-Bind resin according to the manufac- 
turer’s instructions (Novagen). The reaction mixture was passed through 
a 10 ml His-Bind column at 0.5 mllmin, which was then washed with 
30 ml 20 mM Tris-HCI, 250 mM NaCI, 2.5 mM imidazole, pH 7.9 
(1 .O ml/min). Protein was eluted in the same buffer containing 100 mM 
imidazole. Purity and concentration of MbtA-H6 were assessed by 
SDS-PAGE and Bio-Rad protein assay (Bio-Rad), respectively. MbtA- 
HG-containing fractions were dialyzed against 10 mM Tris-HCI (pH 8.0), 
1 mM EDTA, and 5% glycerol. After dialysis, the fractions were aliquot- 
ted, flash frozen in liquid nitrogen, and stored at -80°C. 
Cloning, overproduction and purification of carrier protein 
domains 
For protein overproduction, the E. co/i strains BL21 (DES)/pPptT (over- 
producing the Pptl fusion) and BL21 (DES)pLysS/pMBTA (overproduc- 
ing the MbtA fusion) were cultivated (1 I) with shaking (300 rpm) at 24°C 
in LB broth containing 50 pg/ml kanamycin or 50 pg/ml kanamycin and 
34 Fg/ml chloramphenicol and induced with 0.5 mM isopropyl-l -thio-P-D- 
galactopyranoside (IPTG) when the cultures reached an OD,,, of 0.4. 
After induction, incubation was continued for a period of 3.5 h before the 
cells were harvested by centrifugation (10 min at 2000 x g) and resus- 
pended in 30 ml of a solution of 0.2 M NaCI, 1 mM EDTA, 20 mM Tris- 
HCI, pH 7.4. Following resuspension, cells were disrupted by two 
passages through a French pressure cell (18,000 psi). Cellular debris 
was removed from the lysate by centrifugation (30 min at 95,000 x g). 
The fusion proteins (Figure 1) were purified by affinity chromatography 
The ArCP and the PCP3 coding fragments from mbt5 and mbtf, 
respectively, were amplified by PCR from M. tuberculosis CSU93 
genomic DNA with the primers LQ-95 and LO1 21 (ArCP), and La-1 45 
and La-146 (PCPS), respectively (Table 4). The amplified ArCP and 
PCP3 fragments were digested with Ndel and Hindlll, gel-purified, and 
ligated to the IVdellHindlll 5192 bp vector backbone from plasmid 
plADLl4 to generate the plasmids pARCP and pPCP3, respectively. 
These protein constructs are outlined in Figure 5. The plasmid pARCP 
expresses a translational fusion (MBP-ArCP-H6) in which the MBP and 
the His tag fragments encoded in plADL14 are fused in frame to the 
amino and carboxyl termini, respectively, of the fragment encompassing 
residues l-88 of MbtB. Similarly, the plasmid pPCP3 expresses a 
translational fusion (MBP-PCP3-H6 protein) in which the MBP and the 
His tag fragments from the vector plADLl4 are fused in frame to the 
amino and carboxyl termini, respectively, of the fragment encompassing 
the residues 1570 to 1658 of MbtE. Plasmids pARCP and pPCP3 were 
introduced by transformation into the E. co/i strain DH5a, and then 
transferred to the E. co/i strain BL21(DE3) and BL21(DE3)pLysS, 
respectively, for expression and overproduction of the fusion proteins. 
Protein overproduction in the E. co/i strains BL21 (DES)/pARCP (over- 
producing ArCP fusion) and BL21 (DE3)pLysSlpPCPB (overproduc- 
ing PCP3 fusion) and purification using MBP-tag-based affinity 
Table 4 
Oligonucleotide primers. 
Primer Comments* Sequence 
La-i 21 ArCP forward 5’-GAGATATCATATGGTGCATGCTACGGCGTGCT-3’ 
La-95 ArCP reverse 5’.GTAGTAAGCTTCCCTGGTGCGGCAACTGCCGT-3’ 
La-1 46 PCP3 forward 5’.GGCGGCACATATGCCGGCCGAGCCCGCCGACACCGAAAC-3’ 
La-1 45 PCP3 reverse 5’-CTCATAAGCTTGTGATGCTTGTCGTCCGGCTCGGCC-3’ 
La-i 31 PptT forward 5’-AGATATACATATGACCGTGGGCACCCTGGTGGC-3’ 
La-i 32 PptT reverse 5’.GTTGAAGCmATAGCACGATCGCGGTCAGCACCAGT-3’ 
La-1 54 MbtA forward 5’-GATATCATATGCCACCTAAAGCGGCAGATGGCCGCCGA-3’ 
La-l 26 MbtA reverse 5’-GACGTAAGCTTATGGCAGCGCTGGGTCGTCACGGGA-3’ 
*Forward primers introduce an Ndel site and reverse primers introduce a HindIll site. Restriction sites are bold and italicized. 
644 Chemistry & Biology 1998, Vol 5 No 1 1 
chromatography on amylose resin were carried out as described above 
for the MBP-MbtA-H6 fusion (only the latter strain was grown in the 
presence of both chloramphenicol and kanamycin). Thrombin proteoly- 
sis was carried out at a substrate concentration of 0.33 mg/ml (ArCP 
fusion) and 1 .O mglml (PCP3 fusion) at pH 8.6. For Ni-NTA purification, 
the loading was performed in 20 mM Tris, 600 mM NaCI, 20 mM imida- 
zole, pH 8.6. Washing was performed with the same buffer increased 
to 40 mM imidazole, and elution was accomplished with an imidazole 
gradient increasing from 40 mM to 500 mM over 90 ml. Pure protein 
eluted at about 225 mM imidazole. In this way, the ArCP-H6 fusion 
(retaining the vector-derived Gly-Ser-His fragment and the His tag at 
the amino and carboxyl termini, respectively) and PCP3-H6 fusion 
(retaining the vector-derived Gly-Ser-His-Met fragment and the His 
tag at the amino and carboxyl termini, respectively) were obtained. 
Fractions containing the fusions were dialyzed against 10 mM HEPES, 
100 mM NaCI, 1 mM EDTA, 1 mM DTT, 5% glycerol, pH 8.6 (buffer B), 
and concentrated to approximately 100 FM with a Centriprep 3 con- 
centrator (Amicon). Dialyzed fractions were aliquotted, flash frozen in 
liquid nitrogen and stored at -8O’C. Purity and concentration of carrier 
protein fragments was assessed by SDS-PAGE and absorbance at 
280 nm using the predicted extinction coefficient for ArCP-H6 
(11500 M-‘cm-l) and PCP3-H6 (1400 M-‘cm-r). 
Assay for apo-protein to holo-protein conversion by 
phosphopantetheine group transfer from coenzyme A 
The radioassay for determination of PPTase activity has been previously 
described [31]. Typically, the apo-protein and the [3HlCoA cosubstrate 
were incubated (30 min at 37’C, unless otherwise indicated) with the 
PPTase in a 100 ~1 reaction mixture containing 10 mM MgCI,, 25 mM 
DTT, 75 mM Tris-HCI buffer, pH 7.0. Acetylated [3H]CoA was 
hydrolyzed to the free thiol form as reported previously [351 before its 
addition to the reaction mixture. APO-proteins were added to the reac- 
tion from stocks (-100 PM) in buffer B. Reactions were initiated by 
adding the PPTase in 10 ul of buffer A. Enzyme concentration in the 
assay was typically 25-55 nM, unless otherwise indicated. Reactions 
were quenched with 800 ul of 10% trichloroacetic acid (TCA) with BSA 
(375 ug) added as carrier. Precipitated proteins were pelleted by cen- 
trifugation, and the pellets were washed 3 x with 800 ul of 10% TCA 
before dissolving them in 150 ul of 1 M Tris base. The redissolved pro- 
teins were mixed with 3.5 ml of liquid scintillation cocktail, and the 
amount of radioactivity incorporated was quantified by liquid-scintillation 
counting. Reactions were routinely performed in triplicate. The kinetic 
data (PPTase rate versus substrate concentration) derived from the 
radioassay was fit to the Michaelis-Menten equation or to the general 
substrate-inhibition equation 1361. 
ATP-[s2P]PPj exchange reactions 
ATP-pyrophosphate exchange was assayed as previously described 
[37] with minor modifications. The assay mixture contained 2 mM ATP, 
O-80 PM salicylic acid and 100 nM MbtE-H6 in 10 mM MgCI,, 25 mM 
DTT, and 75 mM Tris-HCI, pH 7.5 (buffer C). Exchange was initiated by 
addition of about 0.5 uCi sodium [32PIpyrophosphate (to 1 mM) in a 
total ,reaction volume of 100 ul. Kinetic experiments were performed 
under linear initial velocity conditions. After incubation at 37°C for 
20 min, the reaction was quenched by the addition of 0.5 ml of a char- 
coal suspension (1.6% (w/v) activated charcoal, 0.1 M tetrasodium 
pyrophosphate, 0.35 M perchloric acid). The charcoal was pelleted by 
centrifugation, washed with 1 ml H,O, resuspended in 0.5 ml H,O, 
added to a scintillation vial containing 3.5 ml scintillation fluid, and the 
bound radioactivity was determined by liquid scintillation counting. 
Covalent incorporation of salicylate into holo-carrier proteins 
For the autoradiographs shown in Figure 8, 40 uM of apo-MBP-ArCP- 
H6, apo-ArCP-H6, or apo-PCP3-H6 was phosphopantetheinylated as 
described above, but with unlabeled CoA (300pM) and MBP-PptT 
(2 pM) for 2-6 h at 37°C. Salicylation was initiated by addition of ATP (to 
8 mM), [‘“C]salicylic acid (55.5 Ci/mol, 60 PM), and enzyme (238 nM 
MbtA-H6, 1 uM EntE, or 1 uM YbtE). After incubation at 37°C for 30 min 
(Figure 8e,f) or 2.5 h (Figure 8c,d), 20 ul of each reaction was run on a 
16% Tris-tricine gel. Gels were stained with Coomassie Blue, soaked in 
Amplify (Amersham) for 30 min, and exposed to film for 1 week. 
For quantification of salicylate incorporation into holo-carrier proteins, 
reactions contained 5 mM holo-ArCP-H6, 400 nM MbtA-H6, 2 mM 
ATP, and 90 mM [i4CJsalicylic acid (55.5 Ci/mol) in buffer C. Reac- 
tions were incubated at 37’C for 15 h and worked up as described 
above for the phophopantetheinylation assay. Kinetic substrate 
versus velocity measurements were performed under linear initial 
velocity conditions. 
Sample preparation for HPLC and mass spectrometry 
Analytical HPLC was performed using a Vydac Cl8 reverse-phase 
column (4.6 mm x 25 cm) on a Beckman Gold HPLC system with moni- 
toring at 220 nM. Samples (1 O-20 ug protein) were eluted at 1 ml/min 
using a linear gradient (23 min) from 35-500/o acetonitrile in 0.1% trifluo- 
roacetic acid. Matrix-assisted laser desorptionionization time-of-flight 
mass spectrometry (MALDI-TOF) on HPLC-purified apo and holo carrier 
proteins was performed at the Howard Hughes Medical Institute Biopoly- 
mers Facility, Harvard Medical School. MALDI-TOF mass spectrometry 
of salicylation reactions was performed at the Biopolymers Laboratory in 
the Department of Biological chemistry and Molecular Pharmacology, 
Harvard Medical School. Phosphopantetheinylation and salicylation reac- 
tions to obtain holo and salicylated carrier proteins were performed under 
conditions similar to those described above, except that unlabeled CoA 
or salicylate were used in place of the radiolabeled substrate. 
Determination of L3HICoA specific activity 
Analytical HPLC of the PCP3 substrate modified with unlabeled CoA 
indicated complete conversion from the apo to the holo form. Addition- 
ally, no holo-PCP3 was detected in the apo-PCP3 preparation prior to in 
vitro phosphopantetheinylation. These observations allowed us to calcu- 
late the effective specific activity in the P-pant portion of our preparation 
of [3H]CoA, by dividing the activity of 13H] incorporated into holo-PCP3 
(under equivalent conditions to those used for incorporation of unlabeled 
CoA) by the moles of protein. Based on this normalized calculation, the 
specific activity in the P-pant portion of the acetylated [3HlCoA was 
determined to be 36 Cilmol. This value was used to calculate the kinetic 
parameters for in vitro modification (see the Results section). 
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